Best Practice & Research Clinical Haematology

Papers
(The median citation count of Best Practice & Research Clinical Haematology is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
Contemporary and future strategies in polycythemia vera75
HLA typing: A review of methodologies and clinical impact on haematopoietic cell transplantation37
The role of randomized controlled trials, registries, observational databases in evaluating new interventions35
Coagulopathy in COVID-19 and anticoagulation clinical trials32
Reducing barriers of access and care related to hematopoietic cell transplantation and cellular therapy: The mission-driven role of the national marrow donor program28
“The state of the science” of childhood, adolescent and young adult Non Hodgkin Lymphoma (NHL)25
Endpoint selection and evaluation in hematology studies24
Asparaginase dosing for obese patients with acute lymphoblastic leukemia and factors that contribute to outcomes24
Allogeneic “Off-the-Shelf” CAR T cells: Challenges and advances22
What are the long-term complications of pediatric ALL treatments and how can they be mitigated? Perspectives on long-term consequences of curative treatment in childhood ALL20
Editorial Board20
The presentation of results from studies in clinical haematology18
Take a spin: Apheresis in the care of adult leukaemia patients14
Targeted cellular therapy for treatment of relapsed or refractory leukemia14
Vaccine-induced immune thrombotic thrombocytopenia12
Creating a GMP cell processing program: A focus on quality and regulation11
Biopathology of childhood, adolescent and young adult non-Hodgkin lymphoma11
How can we improve response assessments in MDS? Strategies to improve response assessment in MDS treatment paradigms10
Cytogenomics of B-cell non-Hodgkin lymphomas: The “old” meets the “new”10
The international cooperative Gaucher group (ICCG) Gaucher registry10
Accelerated and blast phase myeloproliferative neoplasms10
Principles of cost-effectiveness studies and their use in haematology10
What should be done and what should be avoided when comparing two treatments?10
Diagnosis and management of post-transplant lymphoproliferative disease following solid organ transplantation in children, adolescents, and young adults10
Applications and prospects of molecularly targeted drugs combined with CAR-T cell therapy to treat multiple myeloma10
Dysregulation of Protein S in COVID-199
Worldwide sources of data in haematology: Importance of clinician-biostatistician collaboration8
Late effects and frontline treatment selection for children with non-Hodgkin lymphoma8
Editorial Board8
Prevention and treatment of COVID-19 in patients with benign and malignant blood disorders8
Hodgkin Lymphoma: A disease shaped by the tumor micro- and macroenvironment7
Human mesenchymal stem cell therapy: Potential advances for reducing cystic fibrosis infection and organ inflammation7
Corrigendum to “Precision immunomodulation: Understanding and harnessing cytokine pathways to treat and prevent immune-related adverse events (irAEs)” [Best Pract Res Clin Haematol 38 2 2025]7
The role of registries in hematological disorders7
Anti-GM-CSF autoantibodies in myeloid leukemias7
The analysis of multiple outcomes, multiple variables and variables selection in hematopoietic cell transplantation studies7
Addressing symptom burden in myeloproliferative neoplasms7
Is HLA-E with its receptors an immune checkpoint or an antigenic determinant in allo-HCT?7
Handling missing covariate data in clinical studies in haematology7
A reflection on Arnold Caplan, the father of MSC6
Recent progress in acute leukemia and myelodysplasia6
Editorial Board / Aims & Scope6
Corrigendum to “Endpoint selection and evaluation in hematology studies” [Best Pract Res Clin Haematol 36 (2023) 101479]6
Cytokines in hematopoietic cell transplantation and related cellular therapies6
CAR assembly line: Taking CAR T-cell manufacturing to the next level6
The current landscape: Allogeneic hematopoietic stem cell transplant for acute lymphoblastic leukemia6
When to use which molecular prognostic scoring system in the management of patients with MDS?5
What is relative survival and what is its role in haematology?5
Cytogenetics and genomics in CML and other myeloproliferative neoplasms5
Corrigendum to “Designing and conducting a clinical trial in blood and marrow transplantation” [Best Pract Res Clin Haematol 36 (2023) 101471]5
Relevance of donor-specific HLA antibodies in hematopoietic cell transplantation5
Therapeutic initiatives using mesenchymal stem cells and other novel cells in hematology5
Measurable residual disease in patients undergoing allogeneic transplant for acute myeloid leukemia5
The most frequent HLA alleles around the world: A fundamental synopsis5
Shape of the art: TCR-repertoire after allogeneic hematopoietic cell transplantation4
Diagnosis and management of rare paediatric Non-Hodgkin lymphoma4
CARs for lymphoma4
Considerations to comprehensive care for the older individual with myelofibrosis4
Preface of special edition “Biostatistics in clinical haematology”4
Diagnosis and management of ALK-positive anaplastic large cell lymphoma in children and adolescents4
SARS-CoV-2 primary and breakthrough infections in patients with cancer: Implications for patient care4
The correlations among racial/ethnic groups, hypertriglyceridemia, thrombosis, and mortality in hospitalized patients with COVID-194
Diagnosis and management of mature B-cell lymphomas in children, adolescents, and young adults4
Donor lymphocyte infusion in Acute Myeloid Leukemia4
Germline predisposition to myeloid neoplasms: Characteristics and management of high versus variable penetrance disorders3
Cytokines in transplantation tolerance3
Consolidation chemotherapy in AML: Are we playing with a full deck of cards?3
Redox stress in COVID-19: Implications for hematologic disorders3
COVID-19 and antiphospholipid antibodies3
Editorial Board / Aims & Scope3
Designing and conducting a clinical trial in blood and marrow transplantation3
The best GVHD prophylaxis: Or at least progress towards finding it3
Research progress of targeted BCMA CAR-T therapy for relapsed/refractory multiple myeloma antigen-negative relapse3
Editorial Board3
Using real-world evidence in haematology3
Cytokine therapy of acute radiation syndrome3
The Collaborative Biobank (CoBi): Donor and recipient samples & data to facilitate future research on hematopoietic cell transplantation3
Mesenchymal stem cells in hematology: Therapeutic initiatives and future directions3
COVID-19: A hematological perspective3
Diagnosis and management of Hodgkin lymphoma in children, adolescents, and young adults3
Editorial Board / Aims & Scope3
Interfering with KIR and NKG2A immune checkpoint axes to unleash NK cell immunotherapy3
Natural born Killers: Harnessing NK cells to treat cancer2
The Australian Aplastic Anaemia and other Bone Marrow Failure Syndromes Registry2
Analyte heterogeneity analysis as a possible potency parameter for MSC2
HLA-DM and HLA-DO interplay for the peptide editing of HLA class II in healthy tissues and leukemia2
Minor histocompatibility antigens to predict, monitor or manipulate GvL and GvHD after allogeneic hematopoietic cell transplantation2
Transplantation algorithm for myelofibrosis in 2022 and beyond2
Adoptive cellular therapies in multiple myeloma2
Immunopathogenic mechanisms and modulatory approaches to graft-versus-host disease prevention in acute myeloid leukaemia2
Editorial Board2
Cytogenetics and genomics in pediatric acute lymphoblastic leukaemia2
Cytogenetics in haematology2
Allogeneic hematopoietic cell transplantation in acute myeloid leukemia2
CAR-T cell therapy for multiple myeloma: An update on the current state and future potential2
Myeloproliferative neoplasms in adolescents and young adults2
Advancing MSC therapy: The next generation of potent mesenchymal stromal cells for systemic autoimmune rheumatic diseases2
WHO, what, when, where, and why: New classification systems for acute myeloid leukemia and their impact on clinical practice2
Progress and challenges in the acute leukemia field2
Cytogenetics and genomics of acute myeloid leukemia2
How can we intervene to mitigate post-transplantation relapse in AML? Strategies to mitigate post-transplantation relapse in AML2
0.046591997146606